Acumen Pharmaceuticals, Inc.
NASDAQ:ABOS
Overview | Financials
Company Name | Acumen Pharmaceuticals, Inc. |
Symbol | ABOS |
Currency | USD |
Price | 3.17 |
Market Cap | 190,452,966 |
Dividend Yield | 0% |
52-week-range | 1.81 - 5.09 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Daniel J. O'Connell M.B.A. |
Website | https://acumenpharm.com |
An error occurred while fetching data.
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD